CNS Pharmaceuticals Inc (NASDAQ: CNSP), a biopharmaceutical company specialising in the development of novel treatments for primary and metastatic cancers of the brain and central nervous system, has announced that its United States manufacturer, Pharmaceutics International Inc (Pii), has completed the manufacturing process for Berubicin Drug Product, its lead drug candidate intended for the treatment of glioblastoma multiforme (GBM), a difficult to treat brain cancer, it was reported on Tuesday.

The firm has implemented a dual-track drug product manufacturing strategy to mitigate COVID-19-related delay risks, diversify its supply chain and offer localised availability of Berubicin.

According to this strategy, the company has chosen two separate manufacturers for Berubicin on different continents. In the United States, the firm has chosen Pii, which has now completed manufacturing, and in Italy it has chosen BSP Pharmaceuticals SpA. BSP Pharmaceuticals SpA has started the manufacturing process, which is likely to be completed early in the fourth quarter of 2020.